Host Dendritic Cells in Allograft Patients

Inclusion Criteria: * Age 18-70 * Ability to sign informed consent * ECOG performance status ≤3 * Life expectancy \> 6 months * Adequate cardiac function: MUGA or Echocardiogram demonstrating \>50% Ejection Fraction * Adequate pulmonary function with DLCO \> 50% * Adequate hepatic function * Bilirubin ≤ 1.5mg/dl * Alkaline phosphatase ≤5 times the upper limit of normal * Aspartate aminotransferase (AST) or serum glutamic-oxaloacetic transferase (SGOT) ≤ 3 times the upper limit of normal * Alanine aminotransferase (ALT) or serum glutamic pyruvic transaminase (SGPT) ≤ 3 times the upper limit of normal * Adequate renal function Estimated creatinine clearance \> 40ml/min * Diagnosis of one of the following * Non-Hodgkin's lymphoma excluding Follicular lymphoma and Marginal Zone Lymphoma * Hodgkin's lymphoma * Multiple myeloma * Chronic lymphocytic leukemia * Eligible for allogeneic stem cell transplant with identified HLA-identical sibling (6/6 HLA match) or volunteer unrelated donor (8/8 allele HLA-matched (A, B, Cw, DRB1) * Women of childbearing potential must have a negative serum pregnancy test prior to enrollment * Women of childbearing potential must use effective means of birth control throughout the study. * Men should not father a child while enrolled in the study. Effective means of birth control include condom, vasectomy or abstinence. Exclusion Criteria: * Malignancies other than melanoma within five years of study entry, except carcinoma in-situ of the cervix or basal/squamous cell skin cancers * Concurrent illnesses that would preclude survival \> 6 months other than the disease under study * Pregnancy or nursing * HIV infection * Treatment with prior donor lymphocyte infusion * Prior allogeneic stem cell transplant * History of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis and thyroiditis * Active infections including fungal infections and viral hepatitis * GVHD greater than grade I GVHD of the skin Patient Exclusion Criteria for Part B (post Stem Cell Transplant) * Malignancies other than melanoma within five years of study entry, except carcinoma in-situ of the cervix or basal/squamous cell skin cancers * Concurrent illnesses that would preclude survival \> 6 months other than the disease under study. * Pregnancy or nursing * HIV infection * Treatment with prior donor lymphocyte infusion * Prior allogeneic stem cell transplant * More than 4 prior relapses * History of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis and thyroiditis * Active infections including fungal infections and viral hepatitis * GVHD greater than grade I GVHD of the skin * No cytotoxics will be given within 4 weeks of administration of the investigational cell therapy * Patients cannot receive any investigational agents within 30 days prior to administration of the investigational cell therapy